Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00537511 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00537511 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 22 participants.
The verdict
NCT00537511, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose and safety of CC-4047 (pomalidomide) given in combination with cisplatin and etoposide in patients with extensive disease small cell lung cancer.
Interventions
- DRUG Cisplatin
- DRUG Etoposide
- DRUG Pomalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2008-02-01 |
| Est. Completion | 2010-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00537511
The ClinicalTrials.gov registry entry for NCT00537511 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT00537511 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00537511 about?
NCT00537511 is a clinical study titled "A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide". The purpose of this study is to determine the maximum tolerated dose and safety of CC-4047 (pomalidomide) given in combination with cisplatin and etoposide in patients with extensive disease small cell lung cancer.
What is the current status of trial NCT00537511?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2008-02-01. Estimated completion is 2010-12-01.
What interventions are being tested in trial NCT00537511?
The interventions under investigation include: Cisplatin (DRUG), Etoposide (DRUG), Pomalidomide (DRUG).
Who is sponsoring clinical trial NCT00537511?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.